Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Inc. (NYSE: DGX) is a leading provider of diagnostic testing, information, and services in the United States, enabling people to make informed health decisions. The company provides diagnostic insights derived from the world’s largest database of clinical lab results, which aids in identifying and treating diseases, promoting healthy behaviors, and improving healthcare management.
Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States. Its workforce of nearly 50,000 employees is dedicated to transforming lives by providing actionable diagnostic insights. The company offers the broadest test menu available, with over 3,000 different tests, and has a strong focus on cancer diagnostics, anatomic pathology, and interpretive consultations through its medical and scientific staff of approximately 900 M.D.s and Ph.D.s.
In recent years, Quest Diagnostics has been at the forefront of innovation in diagnostic testing. The company has significantly invested in AI and digital pathology to enhance the accuracy and efficiency of cancer diagnoses. A notable collaboration with PathAI aims to accelerate the adoption of digital and AI pathology technologies, thereby improving the quality, speed, and efficiency of diagnosing cancer and other diseases. This partnership includes the acquisition of PathAI Diagnostics’ state-of-the-art digitized laboratory in Memphis, Tennessee, which will serve as Quest’s AI and digital R&D and solutions center.
Financially, Quest Diagnostics has shown robust performance, with annual revenues reaching $7.4 billion in 2014. The company continues to strengthen its market presence through strategic acquisitions and partnerships, expanding its services and enhancing its capabilities in specialized pathology services. The integration of digital and AI technologies across its operations has improved quality, efficiency, and customer satisfaction, positioning Quest Diagnostics as a leader in the diagnostic services industry.
Quest Diagnostics' extensive clinical testing network includes roughly 2,300 patient service centers, numerous doctors' offices, and hospitals nationwide. The company also provides clinical trials testing, risk assessment services, and information technology solutions through its diagnostic solutions segment.
By leveraging its comprehensive diagnostic insights, Quest Diagnostics aims to empower individuals and healthcare providers to make informed decisions that lead to better health outcomes, ultimately contributing to a healthier world.
Quest Diagnostics (NYSE: DGX) has appointed Adrienne L. Brott as senior vice president and chief quality and regulatory affairs officer, effective December 2024. Reporting to CEO Jim Davis, Brott will lead the company's quality and regulatory strategy, focusing on enhancing quality adherence and compliance with global regulations for laboratory diagnostic services.
Brott joins Quest with extensive experience in healthcare quality and regulatory affairs, previously serving as senior vice president of quality and regulatory at Getinge's acute care therapies division. Her prior roles include leadership positions at Becton Dickinson, where she managed quality across 28 manufacturing sites and led a program to harmonize 120 quality management systems. She also held positions at Johnson & Johnson and Abbott Laboratories.
The new executive is co-chair of the Advancing Quality Excellence Collaborative Community Steering Committee of the Medical Device Innovation Consortium, collaborating with stakeholders including the FDA to improve medical device quality and patient safety.
Quest Diagnostics highlighted the humanitarian efforts of Kris Constantino, Director of Logistics Operations, in response to Hurricane Helene in North Carolina. Constantino aided county leaders with supply logistics, particularly in Pensacola, which was isolated and dependent on National Guard air drops. She coordinated with the Product Remanufacturing Center (PRC), an Amazon partner, to secure warehouse space for consolidating donations from Yancey County. Constantino established a logistics network with three strategic storefronts to distribute essential supplies including generators, fuel, warm weather gear, and medical supplies. This recognition is part of Quest's Everyday Heroes Program, which acknowledges employees promoting inclusion, diversity, justice, and equity.
Quest Diagnostics (NYSE: DGX) has scheduled the release of its fourth quarter and full year 2024 financial results for Thursday, January 30, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the results.
Participants can join the call by dialing 888-455-0391 (U.S. and Canada) or 773-756-0467 (international) using passcode '7895081'. The earnings release and webcast will be available on Quest's investor website. A replay will be accessible until February 13, 2025, via phone or the company's investor website.
Quest Diagnostics has released details about its corporate governance and ethics framework in its 2023 Corporate Responsibility Report. The company, with over 56 years of experience and 70 billion data points, maintains strong oversight through its Board of Directors and Executive Leadership team.
Key highlights include:
- Board composition featuring 50% women and/or diverse race/ethnicity representation, with 9 independent members
- Six specialized board committees overseeing various aspects of operations
- 2023 achievements including $343 million spent with small and diverse US businesses
- Over 95% employee completion rate for compliance training
The company has set ambitious 2025/2026 goals, including expanding ESG risk assessments of key suppliers and growing spend with small and diverse suppliers to $500 million. Quest's ESG Council meets quarterly to drive integration of ESG initiatives, while the Enterprise Risk Management program promotes risk awareness throughout operations.
Quest Diagnostics made significant environmental progress in 2023 through multiple sustainability initiatives. The company purchased over 40 million kilowatt hours of renewable electricity and installed electric vehicle charging stations in Marlborough, Tampa, and Atlanta. Their fleet optimization reduced driving by 2.6 million miles, saving 96,000 gallons of gasoline and 845 metric tons of CO2 emissions.
The company implemented waste reduction programs at major California laboratories, diverting over 3,500 tons of medical and municipal waste from landfills, generating 1 million kilowatt-hours of electricity, and avoiding 6,900 tons of CO2-equivalent emissions. Their box optimization project achieved an 11% reduction in shipping boxes, saving 23 tons of cardboard.
Quest also obtained ISO 14001 certifications for facilities in Cleveland HeartLab and Chantilly, joining their San Juan Capistrano lab. The company established an Environmental Health Impact Committee to address climate change's health impacts and inform related policies.
Quest Diagnostics has detailed its comprehensive approach to protecting patient data privacy and cybersecurity. The company maintains a robust privacy program with detailed policies, procedures, and annual HIPAA training for all employees. Their cybersecurity framework, overseen by the Chief Information Security Officer, includes multiple security measures aligned with industry best practices.
The company's cybersecurity program encompasses various domains including IT risk management, access controls, data protection, threat intelligence, and incident response. Quest has established an IT Risk Council for oversight and prioritizes supply chain security by assessing vendor security postures. The program adheres to multiple security frameworks including NIST 800, MITRE 40 ATT&CK, and ISO standards, with oversight from the Board of Directors through specialized committees.
Quest Diagnostics (NYSE: DGX) announced that Chairman, CEO and President Jim Davis will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference in Miami. The presentation, scheduled for December 4, 2024, at 3:00 p.m. Eastern Time, will cover the company's strategy, performance, and current market trends.
The session will be webcast live and accessible through Quest's investor relations page at ir.QuestDiagnostics.com. An archived version will be available within 24 hours after the event and remain accessible until January 3, 2025.
Quest Diagnostics (NYSE: DGX) has launched a new Health Coaching service on questhealth.com through Pack Health®. The service connects individuals with board-certified health advisers for personalized support in areas including general health, weight management, chronic kidney disease, type 2 diabetes, and high cholesterol. The program offers two packages: a 4-session package for $225 and a 6-session package for $275, including one-on-one virtual coaching sessions, regular communication, a welcome kit, and digital content. Customers can integrate their Quest lab results with coaching for a more tailored experience.
Parker Family Health Center (PFHC) in Red Bank, NJ, celebrated its facility expansion with a ribbon-cutting ceremony attended by Quest Diagnostics executives. The renovation includes new exam rooms, conference spaces, private patient areas, and a dedicated phlebotomy room for telehealth services. Quest Diagnostics provides no-cost lab testing through its Quest for Health Equity (Q4HE) initiative.
PFHC has operated for over 23 years, recording nearly 190,000 patient visits, and serves uninsured or underinsured Monmouth County residents. The center maintained operations during its 18-month renovation project and is supported by over 130 volunteers including doctors, nurses, interpreters, and administrative staff.
Quest Diagnostics (NYSE: DGX) announced that its Board of Directors has declared a quarterly cash dividend of $0.75 per share. The dividend will be payable on January 29, 2025 to shareholders of record as of January 14, 2025. This announcement demonstrates the company's continued commitment to returning value to shareholders through regular dividend payments.
FAQ
What is the current stock price of Quest Diagnostics (DGX)?
What is the market cap of Quest Diagnostics (DGX)?
What does Quest Diagnostics do?
How many people does Quest Diagnostics serve annually?
What are some recent achievements of Quest Diagnostics?
What kind of tests does Quest Diagnostics offer?
What is the company's approach to innovation?
How extensive is Quest Diagnostics' clinical testing network?
What role do partnerships play at Quest Diagnostics?
How does Quest Diagnostics contribute to healthcare management?
What are the company’s future plans?
How does Quest Diagnostics ensure the quality of its services?
